Posts Tagged ‘Canadian drug importation’
Connecticut Bioscience Growth Council ED explains why drug importation is “unworkable.”
In this February 24, 2022 editorial published on the Connecticut Business & Industry Association’s website, Paul Pescatello reviews the practical reasons that mean that importing drugs from Canada will not lower prescription drug prices. Pescatello is the executive director of CBIA’s Bioscience Growth Council and chair of We Work for Health Connecticut.
[...]“Reducing costs requires more than all of this non–value-added activity,” Expert Says
In this October 23, 2020 editorial, which was published in the The American Journal of Managed Care, Michael Abrams explains why drug importation will not save patients money. Abrams is the co-founder and managing partner of Numerof & Associates.
[...]Counterfeit Medicine: Crime and Policy, October 20, 2020
A summary briefing of 2020’s major cases, worrying trends and a deep dive into drug supply chain policy issues.
[...]“…barriers will delay or prevent drug importation,” say regulatory experts
In this analysis, which was published in Lexology on October 13, 2020, three global regulatory experts examine barriers to drug importation.
[...]Counterfeit Medicine News for the Week of October 5, 2020
In PSM’s round-up this week: Policy truths about drug importation, prosecutions for fake COVID-19 treatments and financial fraud, and another week in counterfeit pills.
[...]Counterfeit Medicine News for the Week of September 28, 2020
In PSM’s round-up this week: A new report about the counterfeit medicine trade, fake COVID-19 vaccines in India, the week in counterfeit pills.
[...]Counterfeit Medicine News for the Week of September 21, 2020
In PSM’s round-up this week: HHS defies 20 years of expertise and guidance and recent negative feedback to finalize regulations for state-based Canadian drug importation programs, forward movement on the Safe Therapeutics Act, and more #covidscam and counterfeit drug news.
[...]Trump Administration Defies 20 Years of FDA Expertise and Guidance in Finalizing Politically Motivated Drug Importation Rule
Trump Administration Defies 20 Years of FDA Expertise and Guidance in Finalizing Politically Motivated Drug Importation Rule Washington, D.C. (September 24, 2020) – Shabbir Safdar, executive director of the Partnership for Safe Medicines, released the following statement in response to the Trump Administration’s Final Rule issued today on the importation of prescription drugs: “With 40…
[...]Final regulations released governing Canadian drug importation
On September 24th, 2020 the U.S. Department of Health and Human Services released a draft of finalized rulemaking for Importation of Prescription Drugs. Watch this space for the most up-to-date news.
[...]“These drugs would go through additional shipping, inspection and repackaging. Why would they be cheaper?”
In this editorial, which was published in WBUR’s Cognoscenti on September 2, 2020, writer Sarah Ruth Bates explains why Canadian drug importation is too expensive and elaborate a solution to be effective.
[...]